| |
A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. 
|
|
Today’s Big NewsDec 4, 2023 |
| By Nick Paul Taylor,Gabrielle Masson Roche is paying $2.7 billion upfront to enter the obesity market. The takeover will give Roche control of Carmot Therapeutics, a biotech with injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug in clinical development. |
|
|
|
By Angus Liu As AbbVie and Johnson & Johnson, AstraZeneca and BeiGene are battling it out in the same BTK inhibitor market, Eli Lilly is trailblazing a new path for the blood cancer drug class with an accelerated approval in post BTK/BCL-2 chronic lymphocytic leukemia. |
By Annie Burky,Anastassia Gliadkovskaya,Heather Landi,Paige Minemyer,Dave Muoio,Noah Tong Meet our 2023 Women of Influence. Each of the 10 women profiled this year is playing a major role in driving the industry forward. |
By Annalee Armstrong After heralding data last month showing that the multiple sclerosis candidate fenebrutinib may have crossed the blood-brain barrier, Genentech revealed quietly last week that the program has been placed on a partial clinical hold by the FDA in the U.S. |
|
Thursday, December 13, 2023 | 11am ET / 8am PT In this webinar discover how CDMOs drive efficiency, ensure quality, and enable scalability in biologics production and stay ahead in the dynamic world of biologics with a focus on the transformative CDMO impact. Reigster now. 
|
|
By Andrea Park Three years after launching with a first fund of $100 million, Intuitive Surgical’s venture capital arm has gone even bigger with its second funding pool. |
By Annalee Armstrong Shares of Merus fell 6% Monday morning as an interim update for a bispecific therapy revealed three deaths in the lung cancer portion of an ongoing trial. |
By Fraiser Kansteiner WuXi Biologics expects to miss its original sales target for the year by around $400 million, thanks to reductions across its development and manufacturing services. WuXi Bio blamed the projected miss largely on a COVID-related revenue slowdown and a decline in projects. |
By Conor Hale New Mountain bought the lab supply business and brand from PerkinElmer in March via a $2.45 billion deal, and is now combining it with Covaris. |
By Conor Hale The former Fierce Medtech Fierce 15 winner announced it has begun to voluntarily restructure its equity through pre-negotiated terms filed in Delaware bankruptcy court. |
By Helen Floersh Researchers have used unaltered human tracheal cells to create self-assembling multicellular robots capable of healing wounded neurons in a petri dish. |
By Zoey Becker The move is expected to bring in some $95 million in annual sales, the company said. In a separate deal, Sandoz snapped up four Aspen products for $60 million. |
By Gabrielle Masson Seismic Therapeutic has secured a series B of significant magnitude, snagging $121 million and new investor Amgen Ventures in a round aimed at pushing two immunology programs into the clinic. |
By Fraiser Kansteiner Fujifilm is dividing $200 million between a pair of subsidiaries. Those are: Fujifilm Cellular Dynamics, which specializes in development and manufacturing of human induced pluripotent stem cells (iPSC), and the organization’s CDMO for biologics and advanced therapies, Fujifilm Diosynth Biotechnologies. |
By Andrea Park Drug delivery devices are in the safety regulation crosshairs as of late, as a growing list of the technologies have found themselves the subject of recalls and corrections in recent weeks. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
|
Tuesday, December 19, 2023 | 12pm ET / 9am PT Either you want to implement a CLM, or you don’t know how to fix the processes of the one you have in place. Either is a tough place to be in. Join us in this webinar to learn from a CLM solution implementation expert in the highly regulated field of pharmaceuticals. Register now. 
|
|
Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| Edison Ballroom, New York City |
|
|
| |
|
